ChemicalBook > CAS DataBase List > BGT226

BGT226

Product Name
BGT226
CAS No.
915020-55-2
Chemical Name
BGT226
Synonyms
BGT-226 free base;BGT226, 10 mM in DMSO;inhibit,Mammalian target of Rapamycin,BGT226,PI3K,BGT 226,Autophagy,BGT-226,Inhibitor,mTOR,Phosphoinositide 3-kinase;8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one;8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one;2H-Imidazo[4,5-c]quinolin-2-one, 1,3-dihydro-8-(6-methoxy-3-pyridinyl)-3-methyl-1-[4-(1-piperazinyl)-3-(trifluoromethyl)phenyl]-
CBNumber
CB52731024
Molecular Formula
C28H25F3N6O2
Formula Weight
534.53
MOL File
915020-55-2.mol
More
Less

BGT226 Property

storage temp. 
Store at -20°C
solubility 
Soluble in DMSO
form 
Solid
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

TRC
Product number
M226705
Product name
8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl)-3-(trifluoromethyl)phenyl-1H-imidazol[4,5-c]quinolin-2(3H)-one
Packaging
2.5mg
Price
$260
Updated
2021/12/16
AK Scientific
Product number
SYN1178A
Product name
BGT-226freebase
Packaging
100mg
Price
$1615
Updated
2021/12/16
More
Less

BGT226 Chemical Properties,Usage,Production

Uses

8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl)-3-(trifluoromethyl)phenyl-1H-imidazol[4,5-c]quinolin-2(3H)-one is an intermediate used in the screening of anti-prostate cancer drug targeting PI3K-AKT-mTOR pathway.

Definition

ChEBI: BGT226 free base is an imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor. It has a role as an antineoplastic agent, a mTOR inhibitor and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is an imidazoquinoline, a N-arylpiperazine, a member of pyridines, an organofluorine compound and an aromatic ether. It is a conjugate base of a BGT226(1+).

in vivo

BGT226 (2.5 and 5 mg/kg; oral administration for 21 days in male athymic mice) causes 34.7% and 76.1% reduction of the tumor growth on day 21 compared with control[2].

Animal Model:Male athymic mice (strain BALB/cAnN.Cg-Foxn1nu/CrlNarl) with FaDu cell xenografted mouse model[2]
Dosage:2.5 and 5 mg/kg
Administration:Oral administration; 21 days
Result:Caused 34.7% and 76.1% reduction of the tumor growth.

IC 50

PI3Kα: 4 nM (IC50); PI3Kβ: 63 nM (IC50); PI3Kγ: 38 nM (IC50); mTOR; Autophagy

BGT226 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

BGT226 Suppliers

China 23 India 1 United Kingdom 1 United States 4 Global 29
Novachemistry
Tel
44-20819178-90 02081917890
Fax
(0)2080432064
Email
info@novachemistry.com
Country
United Kingdom
ProdList
4381
Advantage
58

915020-55-2, BGT226Related Search:


  • BGT-226 free base
  • 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one
  • 2H-Imidazo[4,5-c]quinolin-2-one, 1,3-dihydro-8-(6-methoxy-3-pyridinyl)-3-methyl-1-[4-(1-piperazinyl)-3-(trifluoromethyl)phenyl]-
  • inhibit,Mammalian target of Rapamycin,BGT226,PI3K,BGT 226,Autophagy,BGT-226,Inhibitor,mTOR,Phosphoinositide 3-kinase
  • 8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
  • BGT226, 10 mM in DMSO
  • 915020-55-2
  • C28H25F3N6O2